Skip to content
Constant Therapeutics

News & Events

Results: 13

Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa (EB)

Constant Pharmaceuticals today announced that it plans to begin a development program for its compound, TXA127, for the treatment of the rare pediatric disease, epidermolysis bullosa in collaboration with four EB focused charities – DEBRA (Austria), Cure-EB, the Epidermolysis Bullosa Research Partnership (EBRP), and the Epidermolysis Bullosa Medical Research Foundation (EBMRF).… Read more »

Tarix Orphan Receives Rare Pediatric Disease Designation for TXA127 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Cambridge, MA (January 18, 2017): Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted a Rare Pediatric Disease (RPD) designation for the company’s drug candidate TXA127 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. There are currently no approved therapies for RDEB and treatment […]

Tarix Orphan Granted Orphan Drug Status for TXA127 as Potential Treatment for Congenital Muscular Dystrophy (MDC1A)

Cambridge, MA (February 17, 2016): Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted Orphan Drug status to the company’s lead compound, TXA127, for the treatment of laminin-­‐deficient congenital muscular dystrophy (LAMA2 MD or MDC1A). Early-­‐onset LAMA2-­‐related muscular dystrophy occurs in approximately 1 in 30,000 individuals and accounts for between […]

Tarix Orphan, LLC Announces Patent Issuance for TXA127 in Treatment of Marfan Syndrome

TXA127 Shows Positive Activity in Fibrilin Model of Marfan Syndrome Cambridge, MA (August 18, 2015): Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering the use of TXA127 in […]